Overall survival was significantly longer in the ramucirumab plus paclitaxel group than in the placebo plus paclitaxel group ( median 96 months [ 95 % CI 85-108 ] vs 74 months [ 95 % CI 63-84 ] , hazard ratio 0807 [ 95 % CI 0678-0962 ] ; p = 0017 ) .